Mar 24, 2009 - Ligand Pharmaceuticals Incorporated today announced that its partner, Pfizer, Inc. (NYSE: PFE) has received approval from the European Commission(EC) for FABLYN (lasofoxifene) Tablets, a selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in post-menopausal women at increased risk of fracture. FABLYN was submitted for approval in Europe in January 2008.
The details can be read here.
No comments:
Post a Comment